Role of plerixafor in autologous stem cell mobilization with vinorelbine chemotherapy and granulocyte-colony stimulating factor in patients with myeloma: a phase II study (PAV-trial)

References

• Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma:Intergroupe Francais du Myelome. N Engl J Med 1996;335:91–97.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006;24:929–936.
   PubMed Web of Science ®Google Scholar
• Bladé J, Rosinol L, Sureda A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005;106:3755–3759.
   PubMed Web of Science ®Google Scholar
• Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875–1883.
   PubMed Web of Science ®Google Scholar
• Fermand JP, Katsahian S, Divine M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005;23:9227–9233.
   PubMed Web of Science ®Google Scholar
• Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998;92:3131–3136.
   PubMed Web of Science ®Google Scholar
• Raschle J, Ratschiller D, Mans S, et al. High levels of circulating CD34 + cells at autologous stem cell collection are associated with favourable prognosis in multiple myeloma. Br J Cancer 2011; 105:970–974.
   PubMed Web of Science ®Google Scholar
• Allan DS, Keeney M, Howson-Jan K, et al. Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2002;29:967–972.
   PubMed Web of Science ®Google Scholar
• Alegre A, Tomas JF, Martinez-Chamorro C, et al. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs. G-CSF alone. Bone Marrow Transplant 1997;20:211–217.
   PubMed Web of Science ®Google Scholar
• Arora M, Burns LJ, Barker JN, et al. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Biol Blood Marrow Transplant 2004;10:395–404.
   PubMed Web of Science ®Google Scholar
• Hiwase DK, Bollard G, Hiwase S, et al. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma. Cytotherapy 2007;9:539–547.
   PubMed Web of Science ®Google Scholar
• Bargetzi MJ, Passweg J, Baertschi E, et al. Mobilization of peripheral blood progenitor cells with vinorelbine and granulocyte colony-stimulating factor in multiple myeloma patients is reliable and cost effective. Bone Marrow Transplant 2003;31:99–103.
   PubMed Web of Science ®Google Scholar
• Bargetzi MJ, Pabst T, Schoenenberger A, et al. Vinorelbine and pegfilgrastim for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: a predictive and cost effective procedure. Bone Marrow Transplant 2009;43(Suppl. 1): S148.
   Google Scholar
• Lévesque JP, Hendy J, Takamatsu Y, et al. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 2003;111:187–196.
   PubMed Web of Science ®Google Scholar
• Donzella GA, Schols D, Lin SW, et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 1998;4:72–77.
   PubMed Web of Science ®Google Scholar
• DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with Non-Hodgkin's lymphoma. J Clin Oncol 2009;27:4767–4773.
   PubMed Web of Science ®Google Scholar
• DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009;113:5720–5726.
   PubMed Web of Science ®Google Scholar
• Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115–1123.
   PubMed Web of Science ®Google Scholar
• Fontana S, Groebli R, Leibundgut K, et al. Progenitor cell recruitment during individualized high-flow, very-large-volume apheresis for autologous transplantation improves collection efficiency. Transfusion 2006;46:1408–1416.
   PubMed Web of Science ®Google Scholar
• Allan DS, Keeney M, Howson-Jan K, et al. Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2002;29:967–972.
   PubMed Web of Science ®Google Scholar
• Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85:588–596.
   PubMed Web of Science ®Google Scholar
• Ketterer N, Salles G, Raba M, et al. High CD34 + cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998;91:3148–3155.
   PubMed Web of Science ®Google Scholar
• Shaughnessy P, Islas-Ohlmayer M, Murphy J, et al. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. Biol Blood Marrow Transplant 2011;17:729–736.
   PubMed Web of Science ®Google Scholar
• Shaughnessy P, Uberti J, Devine S, et al. Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from expanded access program. Bone Marrow Transplant 2013;48:777–781.
   PubMed Web of Science ®Google Scholar
• Dugan MJ, Maziarz RT, Bensinger WI, et al. Safety and preliminary efficacy of plerixafor in combiation with chemotherapy and G-CSF:an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undegoing stem cell mobilization. Bone Marrow Transplant 2010;45:39–47.
   PubMed Web of Science ®Google Scholar
• Chen Al, Bains T, Murray S, et al. Clinical experience with a simple algorithm for plerixafor utilization in autologous stem cell mobilizaton. Bone Marrow Transplant 2012;4:1526–1529.
   Web of Science ®Google Scholar